VRPX — Virpax Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Virpax Pharmaceuticals Says Does Not Hold Any Deposits, Securities, Maintain Any Accounts At, Have Any Other Banking Relationship With, Silicon Valley Bank
Analysis: Biotech IPOs to bloom with spotlight on startups with human trial data
Brief: Virpax Pharmaceuticals to Utilize Dr Singla to Assist in Development of Probudur
Brief: Virpax Pharmaceuticals Receives Notice Of Delisting From Nasdaq
Brief: Virpax Pharmaceuticals Reports On FDA Pre-IND Response For NobrXiol
Brief: Virpax Pharmaceuticals Reports Third Quarter Results
Brief: Virpax Pharmaceuticals Files For Mixed Shelf Of Up To $100 Million
Brief: Virpax Pharmaceuticals Reports Q2 Results, Recent Developments
Brief: Virpax Pursues OTC Medical Device Pathway For Anqlar™
Brief: Virpax Pharmaceuticals Reports 2022 First Quarter Results And Recent Developments
Brief: Virpax Pharmaceuticals Enters Into Crada With The U.S. Army Institute Of Surgical Research
Virpax rises on preclinical data for seizure treatment
Brief: Virpax Reports 2021 Results
Brief: Virpax Pharmaceuticals - Completes All FDA-Required Pre-Clinical Studies For Epoladerm
Brief: Virpax Reports Favorable Preclinical Safety Data For Envelta
Brief: Virpax Successfully Completes Preclinical Dermal Safety Studies For Epoladerm
Brief: Virpax Announces Clinical Trial Site In Canada For First In Human Study Of Epoladerm For Pain Associated With Osteoarthritis Of The Knee
Virpax Pharma rises after promising pre-clinical pain therapy data
Brief: Virpax Reports Successful Results Of Toxicology And Pharmacokinetic Study For Epoladerm